Literature DB >> 20177700

Eponym : Rasmussen syndrome.

Mario Mastrangelo1, Rosanna Mariani, Alessandra Menichella.   

Abstract

Rasmussen's syndrome (RS) is a rare acquired progressive inflammatory encephalopathy characterized by drug-resistant partial seizures and cognitive deterioration resulting from a gradual impairment and a subsequent atrophy of a single brain hemisphere. It was firstly described by Theodore Rasmussen in 1958. The original etiopathogenic hypothesis of a chronic viral infection no longer holds. Today, the presumed mechanism is a complex autoimmune process comprising an active role of both cytotoxic T lymphocytes and circulating autoantibodies, activating the subunit 3 of the ionotropic glutamate receptor (GluR3Ab). Several medical options, such as antiepileptic drugs and immunomodulatory therapies, deserve consideration to face epileptic manifestations and to slow neurologic regression. Yet, all these therapies turn out to be almost always just temporizing measures. Surgical disconnection of the affected hemisphere ("functional hemispherectomy") is the best therapeutic choice to achieve the arrest of the disease, a good seizure control, the block of neurologic decline, and the improvement of patient's quality of life.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20177700     DOI: 10.1007/s00431-010-1148-0

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  41 in total

1.  Antibodies against GluR3 peptides are not specific for Rasmussen's encephalitis but are also present in epilepsy patients with severe, early onset disease and intractable seizures.

Authors:  Renato Mantegazza; Pia Bernasconi; Fulvio Baggi; Roberto Spreafico; Francesca Ragona; Carlo Antozzi; Gaetano Bernardi; Tiziana Granata
Journal:  J Neuroimmunol       Date:  2002-10       Impact factor: 3.478

Review 2.  Advances in pathogenic concepts and therapeutic agents in Rasmussen's encephalitis.

Authors:  Christian G Bien; Christian E Elger; Heinz Wiendl
Journal:  Expert Opin Investig Drugs       Date:  2002-07       Impact factor: 6.206

3.  Focal seizures due to chronic localized encephalitis.

Authors:  T RASMUSSEN; J OLSZEWSKI; D LLOYDSMITH
Journal:  Neurology       Date:  1958-06       Impact factor: 9.910

4.  Longitudinal study of MRS metabolites in Rasmussen encephalitis.

Authors:  R M Wellard; R S Briellmann; J C Wilson; R M Kalnins; D P Anderson; P Federico; G C A Fabinyi; I E Scheffer; A S Harvey; G D Jackson
Journal:  Brain       Date:  2004-04-06       Impact factor: 13.501

5.  Botulinum toxin treatment of facial myoclonus in suspected Rasmussen encephalitis.

Authors:  Nina Browner; Shaheda N Azher; Joseph Jankovic
Journal:  Mov Disord       Date:  2006-09       Impact factor: 10.338

Review 6.  Rasmussen's encephalitis.

Authors:  Yvonne Hart
Journal:  Epileptic Disord       Date:  2004-09       Impact factor: 1.819

7.  Chronic encephalitis and epilepsy in adults and adolescents: a variant of Rasmussen's syndrome?

Authors:  Y M Hart; F Andermann; D R Fish; F Dubeau; Y Robitaille; T Rasmussen; S Berkovic; R Marino; E M Yakoubian; K Spillane; F Scaravilli
Journal:  Neurology       Date:  1997-02       Impact factor: 9.910

Review 8.  Intravenous immunoglobulin in neurological disease: a specialist review.

Authors:  C M Wiles; P Brown; H Chapel; R Guerrini; R A C Hughes; T D Martin; P McCrone; J Newsom-Davis; J Palace; J H Rees; M R Rose; N Scolding; A D B Webster
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-04       Impact factor: 10.154

9.  CD8+ T-cell clones dominate brain infiltrates in Rasmussen encephalitis and persist in the periphery.

Authors:  Nicholas Schwab; Christian G Bien; Anne Waschbisch; Albert Becker; Giles H Vince; Klaus Dornmair; Heinz Wiendl
Journal:  Brain       Date:  2009-01-29       Impact factor: 13.501

10.  Autoantibodies to glutamate receptor GluR3 in Rasmussen's encephalitis.

Authors:  S W Rogers; P I Andrews; L C Gahring; T Whisenand; K Cauley; B Crain; T E Hughes; S F Heinemann; J O McNamara
Journal:  Science       Date:  1994-07-29       Impact factor: 47.728

View more
  1 in total

1.  Cerebral hemiatrophy associated with hippocampal sclerosis following a single prolonged febrile seizure.

Authors:  Iren Orosz; Christoph Härtel; Stefan Gottschalk; Katharina von Hof; Christian G Bien; Jürgen Sperner
Journal:  Eur J Pediatr       Date:  2011-03-18       Impact factor: 3.183

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.